JP2016535054A5 - - Google Patents

Download PDF

Info

Publication number
JP2016535054A5
JP2016535054A5 JP2016527458A JP2016527458A JP2016535054A5 JP 2016535054 A5 JP2016535054 A5 JP 2016535054A5 JP 2016527458 A JP2016527458 A JP 2016527458A JP 2016527458 A JP2016527458 A JP 2016527458A JP 2016535054 A5 JP2016535054 A5 JP 2016535054A5
Authority
JP
Japan
Prior art keywords
formula
xrpd spectrum
peaks
compound
crystalline compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016527458A
Other languages
English (en)
Japanese (ja)
Other versions
JP7045795B2 (ja
JP2016535054A (ja
Filing date
Publication date
Priority claimed from GBGB1319776.9A external-priority patent/GB201319776D0/en
Application filed filed Critical
Publication of JP2016535054A publication Critical patent/JP2016535054A/ja
Publication of JP2016535054A5 publication Critical patent/JP2016535054A5/ja
Priority to JP2021052653A priority Critical patent/JP7346485B2/ja
Application granted granted Critical
Publication of JP7045795B2 publication Critical patent/JP7045795B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016527458A 2013-11-08 2014-11-07 結晶性β-ラクタマーゼ阻害剤 Active JP7045795B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021052653A JP7346485B2 (ja) 2013-11-08 2021-03-26 結晶性β-ラクタマーゼ阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1319776.9A GB201319776D0 (en) 2013-11-08 2013-11-08 Compound
GB1319776.9 2013-11-08
GBGB1408643.3A GB201408643D0 (en) 2013-11-08 2014-05-15 Compound
GB1408643.3 2014-05-15
PCT/EP2014/074108 WO2015067787A1 (en) 2013-11-08 2014-11-07 Crystalline beta-lactamase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021052653A Division JP7346485B2 (ja) 2013-11-08 2021-03-26 結晶性β-ラクタマーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2016535054A JP2016535054A (ja) 2016-11-10
JP2016535054A5 true JP2016535054A5 (enExample) 2017-12-14
JP7045795B2 JP7045795B2 (ja) 2022-04-01

Family

ID=49818360

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016527458A Active JP7045795B2 (ja) 2013-11-08 2014-11-07 結晶性β-ラクタマーゼ阻害剤
JP2021052653A Active JP7346485B2 (ja) 2013-11-08 2021-03-26 結晶性β-ラクタマーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021052653A Active JP7346485B2 (ja) 2013-11-08 2021-03-26 結晶性β-ラクタマーゼ阻害剤

Country Status (14)

Country Link
US (2) US20160289245A1 (enExample)
EP (1) EP3066103A1 (enExample)
JP (2) JP7045795B2 (enExample)
KR (1) KR20160081964A (enExample)
CN (1) CN105873935B (enExample)
AU (1) AU2014345507B2 (enExample)
CA (1) CA2929199C (enExample)
CL (1) CL2016001097A1 (enExample)
EA (1) EA031348B1 (enExample)
GB (2) GB201319776D0 (enExample)
IL (1) IL245386A0 (enExample)
MX (1) MX2016005869A (enExample)
PE (1) PE20160890A1 (enExample)
WO (1) WO2015067787A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201319776D0 (en) * 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
WO2026086730A1 (zh) * 2024-10-21 2026-04-30 齐鲁制药有限公司 恩美他唑巴坦的晶型及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562073A (en) * 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
US6156745A (en) * 1997-12-29 2000-12-05 Research Corporation Technologies, Inc. 2β-substituted-6-alkylidene penicillanic acid derivatives as β-lactamase inhibitors
US7273935B2 (en) * 2003-08-21 2007-09-25 Orchid Chemicals & Pharmaceuticals, Ltd. Process for the preparation of 3-methylcepham derivatives
US7417143B2 (en) * 2004-04-07 2008-08-26 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of Tazobactam in pure form
US7687488B2 (en) * 2006-07-12 2010-03-30 Orchid Chemicals & Pharmaceuticals Ltd. 2-substituted methyl penam derivatives
NZ610247A (en) * 2010-11-25 2014-09-26 Allecra Therapeutics Gmbh Β-lactamase inhibitors and their use
EP2847205A4 (en) * 2012-05-07 2016-01-20 Univ California NOVEL OXYSTEROL ANALOGUE OXY149 FOR THE INDUCTION OF OSTEOGENESIS AND HEDGEHOG SIGNAL PATH AND THE INHIBITION OF ADIPOGENESIS
US9683009B2 (en) * 2013-05-02 2017-06-20 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
GB201319776D0 (en) 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
GB201408649D0 (en) * 2014-05-15 2014-07-02 Allecra Therapeutics Sas Method
KR20170101940A (ko) * 2014-12-09 2017-09-06 워쏘우 오르쏘페딕 인코포레이티드 스테롤 관련 화합물 및 방법

Similar Documents

Publication Publication Date Title
JP2018528199A5 (enExample)
JP2020500906A5 (enExample)
JP2014501282A5 (enExample)
JP2021501127A5 (enExample)
JP2016537346A5 (enExample)
JP2020530473A (ja) ロキサデュスタットの多形および共結晶
WO2016107289A1 (zh) 制备索非布韦晶型6的方法
JP2019523273A (ja) ベリノスタットの多形形態、およびその調製のためのプロセス
WO2011007895A1 (ja) 貧溶媒添加法による2-(3-シアノ-4-イソブチルオキシフェニル)-4-メチル-5-チアゾールカルボン酸の結晶多形体の製造方法
JP2022060192A5 (enExample)
TWI353970B (enExample)
CN102675395B (zh) 醋酸乌利司他的多晶型及其制备方法
JP2005529082A5 (enExample)
TW201217363A (en) Process for obtaining olmesartan medoxomil
TW201546045A (zh) 新穎結晶性芳烷基胺化合物及其製造方法
TWI756173B (zh) 製備啶醯菌胺之方法
CN107033094A (zh) 一种药物共晶的晶型及其制备方法和组合物
US9745264B2 (en) Method for preparing silodosin and intermediate thereof
WO2016110798A1 (en) An improved process for the preparation of lurasidone and its intermediate
CN104447447A (zh) 一个新的化合物及其制备方法和消除方法
JP6210599B2 (ja) 4−メチル−6(1−メチルベンズイミダゾール−2−イル)−2−n−プロピル−1H−ベンズイミダゾールの製造方法
CN109180564B (zh) 一种哌啶及其衍生物的制备方法
CA2930089C (en) Fingolimod hydrochloride process
JP2021530550A (ja) ブロモドメイン阻害剤の合成方法
CN103113348B (zh) 枸地氯雷他定的假多晶型及其制备方法